Adverse events resulting in withdrawal of biologic therapy for psoriasis in real-world clinical practice: A Canadian multicenter retrospective study - 15/07/15
Abstract |
Background |
Safety profiles of biologics for treatment of psoriasis are limited to data from randomized controlled trials. There is a need for comparative safety reports of biologics based on data from clinical practice.
Objective |
We sought to estimate and compare the incidence of adverse events (AEs) leading to withdrawal of biologics (etanercept, infliximab, adalimumab, and ustekinumab) in the treatment of psoriasis.
Methods |
We conducted a multicenter retrospective chart review from September 2005 to September 2014. Incidence proportion and rate of AEs leading to withdrawal by biologic agent and AE were calculated.
Results |
For 545 treatments administered in 398 patients, 22 (4.04%) AEs were associated with withdrawal, for a rate of 1.97/100 patient-years (95% confidence interval [CI] 1.32-2.94). Common AEs were injection-/infusion-site reactions (0.55%, 0.92%, 0%, and 0% for etanercept, infliximab, adalimumab, and ustekinumab, respectively); infections (0%, 0.18%, 0.55%, 0.18%); and malignancies (0.18%, 0.18%, 0%, 0.37%).
Limitations |
Possible incompleteness of chart details and small study population limit the conclusiveness of findings.
Conclusion |
Biologic agents for treatment of psoriasis are safe; AEs associated with withdrawal occurred in 4% of all administered biologic therapies. It does not appear that real-world patients encounter more AEs with biologics than patients in clinical trials.
Le texte complet de cet article est disponible en PDF.Key words : adverse event, biologic, clinical practice, psoriasis, real world, safety, tumor necrosis factor inhibitor
Abbreviations used : AE, CI, RCT
Plan
| Funding sources: None. |
|
| Conflicts of interest: Dr Yeung has been a speaker, consultant, and investigator for Abbvie, Amgen, and Janssen. Mr Kim, Mr Marinas, Ms Qiang, Mr Shahbaz, and Mr Greaves have no conflicts of interest to declare. |
|
| Reprints not available from the authors. |
Vol 73 - N° 2
P. 237-241 - août 2015 Retour au numéro
Article précédent
- T-cell clonality assessment by next-generation sequencing improves detection sensitivity in mycosis fungoides
- Kari E. Sufficool, Christina M. Lockwood, Haley J. Abel, Ian S. Hagemann, Jonathan A. Schumacher, Todd W. Kelley, Eric J. Duncavage
- Prevalence of undiagnosed psoriatic arthritis among psoriasis patients: Systematic review and meta-analysis
- Axel Patrice Villani, Marie Rouzaud, Morgane Sevrain, Thomas Barnetche, Carle Paul, Marie-Aleth Richard, Marie Beylot-Barry, Laurent Misery, Pascal Joly, Michel Le Maitre, Selim Aractingi, François Aubin, Alain Cantagrel, Jean-Paul Ortonne, Denis Jullien
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?